Downloads
Abstract
Aims: To analyze the dislipidemia level and evaluating the effectiveness of controlling blood lipids in patients with cerebral infarction at 108 Military Center Hospital.
Methods: A descriptive study was conducted on 60 patients who had acute cerebral infarctions not caused by heart or aorta and were treated at the stroke department, 108 Military Center Hospital, from September 2022 to August 2023.
Results: 21.7% of patients were diagnosed with blood lipid disorder, with the average LDL-C at 3,3 ± 0,87 mmol/l. The patients who had cerebral infarction originating from significant atherosclerosis had higher indexes (cholesterol, HDL, triglyceride) and lower LDL indexes than ones creating small embolisms (p > 0.05). However, these indexes (cholesterol, HDL-C, LDL-C, triglyceride) decreased after 3 months with LDL ≤ 1,4 mmol/L: 13,3%, LDL ≤ 1,8mmol/L: 31,6 %. Rosuvastatin 20mg is higher than 10mg and 5mg in reduced cholesterol, LDL-C, and triglyceride levels after 3 months of treatment (14.8% is LDL-C ≤ 1,4 mmol/L, 40.7% is LDL ≤ 1,8 mmol/L). There was no difference in decreasing lipids levels among the contents of rosuvastatin.
Conclusion: The lipid blood disorder rate of the cerebral infarction group is 21.7%. The proper goal of LDL-C after 3 months of treatment is low (13,3%). 20mg rosuvastatin is the most effective in reducing LDL-C.
References
Nguyễn Văn Chương. Điều trị đột quỵ não chung, in Thực hành lâm sàng thần kinh học. 5th Editor. 2018, Nhà xuất bản Y học Hà Nội.
Lê Văn Thính. Điều trị đột quỵ thiếu máu não. Thực hành lâm sàng thần kinh học. 5th Editor. 2018, Nhà xuất bản Y học Hà Nội.
Tsao CW, Aday AW, Almarzooq ZI, Alonso A, Beaton AZ, Bittencourt MS, et al., Heart Disease and Stroke Statistics-2022 Update: A
Report From the American Heart Association. Circulation, 2022;145(8):e153-e639.
Khánh NGP, Đánh giá kết quả kiểm soát LDL-C trong sử dụng thuốc điều trị rối loạn Lipid máu và một số yếu tố liên quan trên bệnh nhân điều trị ngoại trú tại Cần Thơ. Tạp chí y học Việt Nam, 2023;525-1B.
Nishikido T, Oyama J, Keida T, Ohira H, Node K, High-dose statin therapy with rosuvastatin reduces small dense LDL and MDA-LDL:
The Standard versus high-dose therApy with Rosuvastatin for lipiD lowering (SARD) trial. J Cardiol, 2016;67(4):340-6.
Adams SP, Sekhon SS, Wright JM, Lipid-lowering efficacy of rosuvastatin. Cochrane Database Syst Rev, 2014;2014(11):Cd010254.
Kaneko K, Saito H, Sasaki T, Sugawara S, Akasaka M, Kanaya T, et al., Rosuvastatin prevents aortic arch plaque progression and
improves prognosis in ischemic stroke patients. Neurol Res, 2017;39(2):133-141.
Trương Văn Lâm. So sánh hiệu quả rosuvastatin và atorvastatin trong điều trị rối loạn lipid máu. Kỷ yếu hội nghị khoa học Bệnh viện An Giang. 2016. Số tháng 10.
| Published | 29-12-2024 | |
| Fulltext |
|
|
| Language |
|
|
| Issue | No. 90 (2023) | |
| Section | Original article | |
| DOI | 10.38103/jcmhch.90.20 | |
| Keywords |
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright (c) 2023 Journal of Clinical Medicine Hue Central Hospital